Medicare Benefits Schedule - Item 73342

Search Results for Item 73342

Category 6 - PATHOLOGY SERVICES

73342

73342 - Additional Information

Item Start Date:
01-Jan-2016
Description Updated:
01-Jan-2016
Schedule Fee Updated:
01-Jan-2016

Group
P7 - Genetics

An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $315.40 Benefit: 75% = $236.55 85% = $268.10


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change